The FDA has cleared the research organization's investigational new drug application, allowing it to start clinical tests of the experimental treatment DT2-SCT.
As drugmakers take lessons from oncology in developing CAR T cells for other diseases, they must contend with risks that ...
The bill would establish the right of cancer patients to access advanced care, including precision medicine and genomic testing, in their communities.
The agency had previously recommended against marketing authorization for the Alzheimer's disease but reconsidered after a review.
The panels assess genes with strong disease links and clinical management guidelines, but the firm offers limited-evidence genes as an add-on option.
This is the first gene therapy for AADC deficiency to receive US regulatory approval and the first that can be administered directly to the brain.
The pharmaceutical distributor has launched InspiroGene, a business unit offering logistics and other support for ...
A 31-year-old woman with stage IV breast cancer learns a test ordered more than a year before her diagnosis detected a TP53 ...
NEW YORK – Syros Pharmaceuticals said on Tuesday that its retinoic acid receptor-alpha agonist tamibarotene, which it was testing in combination with azacitidine in patients newly diagnosed with ...
In the deal, Nippon Shinyaku can exclusively sell ATSN-101 in the US and develop and sell it in Japan, while Atsena retains rights to other territories.
A Phase I study of invikafusp alfa presented at SITC provided the rationale to enroll patients with TMB-high, MSI-high, and virus-associated tumors in Phase II.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback